Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05577364 | Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients | unknown | Phase 1 / Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT05673694 | To Evaluate a Phase Ia/Ib Clinical Study of EG017 in Patients With Advanced Breast Cancer. | unknown | Phase 1 | 70 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 14, 2023 | clinicaltrials |
| NCT04431648 | Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients With Head and Neck Cancer(USmBRT-H) | unknown | Phase 1 | 20 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06168552 | Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer(CISPD-6) | unknown | Phase 1 / Phase 2 | 20 | Zhejiang UniversityOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT04407741 | Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT04727008 | CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma | unknown | Phase 1 | 12 | Sichuan UniversityOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT06165822 | A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets | unknown | Phase 1 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 12, 2023 | clinicaltrials |
| NCT06166472 | A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor | unknown | Phase 1 | 72 | AkesoINDUSTRY | 1 | Dec 12, 2023 | clinicaltrials |
| NCT04739293 | Study of ON 123300 in Patients With Advanced Cancer | unknown | Phase 1 | 36 | Traws Pharma, Inc.INDUSTRY | 1 | Dec 7, 2023 | clinicaltrials |
| NCT05432934 | Transversus Abdominis Plane Blocks With and Without Dexamethasone(TAP-DEX) | unknown | Phase 1 / Phase 2 | 60 | University of SaskatchewanOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT05113069 | A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas | unknown | Phase 1 | 170 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04450732 | Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors | unknown | Phase 1 | 96 | GeneQuantum Healthcare (Suzhou) Co., Ltd.INDUSTRY | 3 | Dec 5, 2023 | clinicaltrials |
| NCT02004275 | Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma | unknown | Phase 1 / Phase 2 | 118 | Alliance for Clinical Trials in OncologyOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT05280275 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | unknown | Phase 1 / Phase 2 | 36 | Hellenic Society of HematologyOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT02935205 | Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 38 | Mamta ParikhOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03064269 | CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia | unknown | Phase 1 | 10 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03614858 | CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. | unknown | Phase 1 / Phase 2 | 20 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03896854 | CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 15 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05732948 | PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer | unknown | Phase 1 | 12 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05886868 | Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors | unknown | Phase 1 | 66 | Shanghai Best-Link Bioscience, LLCINDUSTRY | 2 | Nov 29, 2023 | clinicaltrials |
| NCT06149611 | Mass Balance Study of TQB3616 | unknown | Phase 1 | 8 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05088889 | Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer | unknown | Phase 1 | 10 | Sheba Medical CenterOTHER_GOV | 1 | Nov 28, 2023 | clinicaltrials |
| NCT04190823 | A Study of RC98 in Subjects With Advanced Malignant Solid Tumors | unknown | Phase 1 | 63 | RemeGen Co., Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT04894825 | Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China | unknown | Phase 1 | 152 | FutureGen Biopharmaceutical (Beijing) Co., LtdINDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT05101265 | Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment | unknown | Phase 1 | 24 | PharmaMarINDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT06147362 | 68Ga-NOTA-PEG2-RM26 PET/CT, First in Man Study | unknown | Phase 1 | 50 | Karolinska University HospitalOTHER | 1 | Nov 27, 2023 | clinicaltrials |
| NCT05580445 | Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 114 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT02557321 | PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma | unknown | Phase 1 / Phase 2 | 50 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT03600649 | Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas | unknown | Phase 1 | 50 | Salarius Pharmaceuticals, LLCINDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT03582514 | PreOperative Brain Irradiation in Glioblastoma(POBIG) | unknown | Phase 1 | 18 | The Christie NHS Foundation TrustOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04253145 | Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer. | unknown | Phase 1 / Phase 2 | 184 | Fundacion OncosurNETWORK | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04338763 | RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer | unknown | Phase 1 | 48 | Rise Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04906044 | Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer(STARS-RC03) | unknown | Phase 1 | 46 | The First Hospital of Jilin UniversityOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06136910 | Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06124001 | Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 36 | CNBG-Virogin Biotech (Shanghai) Ltd.INDUSTRY | 0 | Nov 15, 2023 | clinicaltrials |
| NCT06126237 | A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 120 | Keymed Biosciences Co.LtdINDUSTRY | 0 | Nov 13, 2023 | clinicaltrials |
| NCT04343859 | A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 | 96 | Tianjin Chasesun Pharmaceutical Co., LTDINDUSTRY | 1 | Nov 9, 2023 | clinicaltrials |
| NCT05115292 | A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma | unknown | Phase 1 | 85 | BJ Bioscience, Inc.INDUSTRY | 1 | Nov 9, 2023 | clinicaltrials |
| NCT05681000 | Tolerability of Utidelone Capsule in Patients With Advanced Solid Tumors | unknown | Phase 1 | 28 | Biostar Pharma, Inc.INDUSTRY | 1 | Nov 9, 2023 | clinicaltrials |
| NCT02229656 | Olaparib and Radiotherapy in Head and Neck Cancer | unknown | Phase 1 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05580107 | MDPK67b in Patients With Prostate Cancer | unknown | Phase 1 | 15 | Med Discovery SAINDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06059508 | Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors | unknown | Phase 1 | 100 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06116240 | A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors | unknown | Phase 1 | 135 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 3, 2023 | clinicaltrials |
| NCT05094804 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | unknown | Phase 1 / Phase 2 | 172 | OncoResponse, Inc.INDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06087419 | A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients | unknown | Phase 1 / Phase 2 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Nov 2, 2023 | clinicaltrials |
| NCT06111326 | BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 83 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Nov 1, 2023 | clinicaltrials |
| NCT04097002 | First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. | unknown | Phase 1 / Phase 2 | 24 | Orca Therapeutics B.V.INDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT04156347 | Topotecan Episcleral Plaque for Treatment of Retinoblastoma | unknown | Phase 1 | 42 | Targeted Therapy Technologies, LLCINDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT04519476 | Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. | unknown | Phase 1 | 22 | OncotherapeuticsINDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Dec 14, 2023source: clinicaltrials